Jame Abraham, MD, FACP, Director of the Breast Oncology Program at the Taussig Cancer Institute of the Cleveland Clinic in Ohio, said he believes neratinib is “an extremely active drug, once we learn how best to give it.” Dr. Abraham has been involved in some of the studies of neratinib.
“In this exploratory analysis, we are seeing a signal. The analysis showed that even after giving trastuzumab [Herceptin] for 1 year, patients can still derive some benefit. The question will be where this drug will fit into our armamentarium,” Dr. Abraham said. ■
Disclosure: Dr. Abraham reported no potential conflicts of interest.
An exploratory analysis of the ExteNET study of neratinib in early HER2-positive breast cancer after treatment with trastuzumab (Herceptin) upheld the findings previously reported for the 2-year analysis, according to the study’s principal investigator Arlene Chan, MD, of the Breast Cancer...